Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

1161P - Therapeutic outcome of molecular profiling of melanoma patients resistant to standard treatment: Real-world data

Date

21 Oct 2023

Session

Poster session 13

Topics

Molecular Oncology;  Cancer Diagnostics;  Therapy

Tumour Site

Melanoma;  Merkel Cell Carcinoma

Presenters

Madona SAKKAL

Citation

Annals of Oncology (2023) 34 (suppl_2): S651-S700. 10.1016/S0923-7534(23)01941-5

Authors

M. SAKKAL1, M. Aldea2, A. Bayle3, D. Vasseur4, E. Routier5, D. Belkadi-Sadou6, A. Marchand7, A. Gazzah2, C. Smolenschi8, R. Bahleda9, C. Baldini10, S. Champiat11, Y. Loriot12, L. Lacroix13, E. Rouleau14, A. hollebecque15, A. Italiano15, S. Ponce Aix1, C. Robert16

Author affiliations

  • 1 Drug Development Department (ditep), Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 2 Medical Oncology Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 3 Digestive Oncology Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 4 Molecular Biology, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 5 Medical Oncology Department, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 6 Medical Oncology Department, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 7 Medical Oncology Department, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
  • 8 Digestive Oncology Department, Gustave Roussy, 94805 - VILLEJUIF/FR
  • 9 Drug Development Department, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 10 Drug Development Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 11 Drug Development Department (ditep), Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 12 Cancer Medicine Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 13 Medical Biology And Pathology Department, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 14 Tumor Genetics, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 15 Ditep, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 16 Dermatology Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1161P

Background

Therapeutic options for advanced melanoma patients (pts) resistant to standard treatment (Tx): immunotherapy & anti-BRAF-based targeted therapy represent a high medical need. Objective: Our aim was to evaluate the applicability of precision medicine in melanoma pts who failed standard tx based on molecular profiling (MP) of their tumors & the resulting clinical outcome.

Methods

All pts with advanced melanoma resistant to standard tx who had a MP at Gustave Roussy between April 2021 & March 2023 were included in this retrospective study. MP was performed by using Next Generation sequencing by using Foundation one CDX/liquidCDX & it was based on 3 protocols: STING (NCT04932525), MCLA-128 (NCT03321981) & STARTRK (NCT02568267) which allowed liquid & tissue biopsies studies. Molecular actionability was based on ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) classification.

Results

We performed MP for 184 pts: 174 had melanoma, 2 pts with EWSR1-ATF1 fusion & 1 with EWSR1-CREB1, which allowed a diagnosis correction to clear cell sarcoma & the initiation of the appropriate sarcoma tx, 3 BCC, 3 cSCC & 1 Merkel cell cancer. For the 174 melanoma pts, apart from the BRAF V600 mutation (50% of the pts), a putative actionable molecular orientation was found in 51.6% of the pts. The most frequent molecular alterations were: NRAS (23.2%), PTEN (12.6%), ATM (8.4%), CDKN2A (7.4%), BRAF class II (6.3%), BRAF class III (5.3%), KIT (4.2%) PIK3CA (3.2%), MAP2K1 (3.2%), NF1 (2.1%), AKT (1.1%), HRAS (1.1%), MET (1.1%), ALK (1.1%), ARID1A (1.1%), CDK4 (1.1%), CCND1 (1.1%). Molecularly matched tx was administered to 15 pts: anti-MEK (n = 11) & imatinib (n = 2). Among the 11 pts on anti-MEK, 1 partial response was seen after 9 months of tx & the remaining 10 pts rapidly progressed after 1-3 months of anti-MEK tx as for the 2 pts on imatinib. Unfortunately, no precision medicine tx was available to target the other potentially actionable mutations at the time they were needed.

Conclusions

Potentially actionable mutations can be found in more than 50% of pts with resistant melanoma. Tumor agnostic trials based on molecular alterations should be more broadly available to evaluate the potential benefit of innovative precision medicine in this population.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.